PTC Therapeutics, Inc. (PTCT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 34.03 |
| Open | 33.94 |
| Bid | 33.05 x 200 |
| Ask | 33.14 x 400 |
| Day's range | 32.88 - 33.94 |
| 52-week range | 17.53 - 59.84 |
| Volume | |
| Avg. volume | 866,974 |
| Market cap | 2.538B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.69 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.27 |
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Investor's Business DailyPTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
© 2024 Yahoo. All rights reserved.